Supervisory Board Members

Prof. Dr Iris Löw-Friedrich Chief Medical Officer of UCB S.A., Chairperson of the Supervisory Board of Evotec SE

Prof. Dr Iris Löw-Friedrich (born in 1960, German citizen) was appointed Member of the Supervisory Board on 17 June 2014 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Since 15 June 2021 she has been serving as chairwoman of the Supervisory Board. Her current term will expire at the end of the Annual General Meeting held in the year 2024.

Since March 2008, Prof. Dr Iris Löw-Friedrich is serving as Chief Medical Officer and Executive Vice President Development and Medical Practices of UCB S.A., Brussels (Belgium).

From 2001 to 2009, Prof. Dr Löw-Friedrich was a member of the Executive Board of Schwarz Pharma AG, Monheim am Rhein, with global responsibility for research and development. From 2000 to 2001, she served as Vice President Global Projects at BASF Pharma, Ludwigshafen.

From 1992 to 2000, Prof. Dr Löw-Friedrich held various positions in the area of drug development at Hoechst AG, Frankfurt am Main, lastly as Vice President Clinical Development at Hoechst Marion Roussel/Aventis, Bridgewater, NJ, USA.

Since April 2014, she has been Member of the Board of Directors at TransCelerate BioPharma Inc (Chairman of the Board of Directors from September 2015 until September 2017). TransCelerate BioPharma Inc is a non-profit organisation with membership of 20 major life science companies, including UCB.

Since May 2016, Prof. Dr Löw-Friedrich has been serving as Member of the Supervisory Board of Fresenius SE & Co. KGaA. Prof. Dr Löw-Friedrich began her career in 1985 as a physician in the field of internal medicine at the University of Frankfurt/Main, Medical School, where she has also been a clinical professor for internal medicine since 2000.

She studied medicine at the University of Frankfurt/Main, receiving her doctorate from this university in 1985. Prof Dr Iris Löw-Friedrich is independent in the opinion of the Company. Her position on the Executive Board of UCB S.A., which has a business relationship with Evotec SE, does not constitute dependency. Business relationships constitute a material and prolonged conflict of interest only in exceptional cases. The Supervisory Board has no influence on the volume of orders or the continuation or expansion of business relationships. This is the responsibility of the Management Board of Evotec SE, which not only represents the Company (section 78 of the German Stock Corporation Act (AktG)), but also makes decisions on these matters under its own responsibility (section 76, paragraph 1 of the German Stock Corporation Act (AktG)). There is also no intersecting executive body position.

 

Latest update: June 2021

Roland Sackers Chief Financial Officer and Managing Director of QIAGEN N.V., Vice Chairman of the Supervisory Board of Evotec SE

Mr Roland Sackers (born in 1968, German citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. Since 15 June 2021 he is Vice Chairman of the Supervisory Board. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Mr Sackers has been serving as Chief Financial Officer of QIAGEN N.V. since January 2004. In this position, he is responsible for developing and executing the long-term financial planning, which is the foundation for the company’s accelerated growth strategy.

Prior to joining QIAGEN in 1999, Mr Sackers served as Auditor at the auditing company Arthur Andersen.

Mr Sackers received his master’s degree in Business Administration from the University of Münster.

He represents QIAGEN as board member of BIO Deutschland e.V. Mr Roland Sackers (CFO of Qiagen N.V.) is independent. Qiagen N.V. has no significant business relationship with Evotec SE, and no other circumstances leading to dependency are apparent.

 

Latest update: June 2021

Kasim Kutay Vorstandsvorsitzender der Novo Holdings A/S

Herr Kasim Kutay (Jahrgang 1965, britischer Staatsbürger) wurde am 16. Juni 2020 in den Aufsichtsrat der Evotec SE gewählt. Seine Amtszeit endet mit dem Ende der Hauptversammlung, die über die Entlastung der Mitglieder des Aufsichtsrats für das Geschäftsjahr 2023 der Gesellschaft beschließt.

Herr Kutay ist seit September 2016 Vorstandsvorsitzender der Novo Holdings A/S.

Von 2009 bis 2016 war Herr Kutay Managing Director, Co-Head of Europe und Mitglied des Global Management Committee bei Moelis & Co.

Zuvor war Herr Kutay 18 Jahre bei Morgan Stanley in verschiedenen internationalen, leitenden Führungspositionen tätig, unter anderem als Chairman der European Healthcare Group. Herr Kutay hat in diesen Positionen mit Healthcare-Unternehmen auf internationaler Basis zusammengearbeitet, darunter Unternehmen mit Sitz unter anderem in Europa, den USA, Japan und Indien.

Zu Herrn Kutays weiteren Führungspositionen gehören die Tätigkeit als Aufsichtsratsmitglied bei Novo Nordisk A/S und Novozymes A/S. Er machte seinen Abschluss als Master of Science an der London School of Economics.

Herr Kasim Kutay ist trotz seiner Vorstandsstellung bei der Novo Holding A/S als unabhängiges Aufsichtsratsmitglied anzusehen. Die Novo Holding A/S hält an der Evotec SE 10,58 % der stimmberechtigten Aktien und ist damit kein kontrollierender Aktionär. Eine zur Unabhängigkeit des Aktionärs (und damit auch von Herrn Kutay) führende Kontrolle wäre gegeben, wenn ein Beherrschungsvertrag mit dem Aktionär besteht, der Aktionär über die absolute Mehrheit der Stimmrechte oder zumindest über eine nachhaltige Hauptversammlungsmehrheit verfügt. Ein Stimmanteil von 10,58 % begründet keine nachhaltige Hauptversammlungsmehrheit zugunsten der Novo Holding A/S und damit keinen Interessenkonflikt, zumal die Anzahl gültig abgegebener Stimmen in den vergangenen Hauptversammlungen regelmäßig deutlich über 40 % des Grundkapitals ausmachte.

 

Letzte Aktualisierung: Juni 2021

Dr Mario Polywka Consultant

Dr Mario Polywka (born in 1963, British citizen) was appointed Member of the Supervisory Board on 19 June 2019 for a term of five years. His current term will expire at the end of the Annual General Meeting held in the year 2024.

Dr Polywka retired from the Management Board of Evotec AG effective 31 December 2018. Until then, he served as member of the Management Board and Chief Operating Officer of Evotec AG since 28 November 2007.

In 1991, he was a founding chemist of Oxford Asymmetry International plc (OAI), became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr Polywka was appointed Chief Operating Officer and in 2000 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies from Oxford and Southampton Universities.

Dr Polywka received his Bachelor’s degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillin with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994.

Dr Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.

In May 2017, Dr Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc. and in September 2017, Dr Mario Polywka also joined the Board of Directors of Exscientia Ltd. In September 2019, Dr Polywka was appointed Non-Executive Director at the UK biotech company Orbit Discovery, and has accepted a position as Senior Advisor with MCF Corporate Finance.

Dr Mario Polywka, who served as COO of Evotec until 31 December 2018 and who was elected to the Supervisory Board on the recommendations of a group of shareholders who together hold more than 25% of the total number of voting rights in the Company, is regarded as not independent.

 

Latest update: June 2021

Dr Elaine Sullivan CEO of Curadh Pharmaceuticals and Advisor to the Board of Directors of Carrick Therapeutics Ltd.

Dr Elaine Sullivan (born in 1961, British citizen) was appointed Member of the Supervisory Board on 09 June 2015 and was re-elected as Member of the Supervisory Board by the Annual General Meeting 2019 on 19 June 2019 for a term of five years. Her current term will expire at the end of the Annual General Meeting held in the year 2024.

Since April 2020, Dr Sullivan is CEO of Curadh Pharmaceuticals. From 2015 to 2019, Dr Sullivan was Chief Executive Officer of Carrick Therapeutics Ltd, a European oncology company, which she continues to support as Executive Entrepreneur and Advisor to the Board of Directors.

Elaine Dr Sullivan has worked as part of top management teams in R&D at Eli Lilly and AstraZeneca. She has over 25 years of international experience working in the Pharmaceutical industry in the USA and the UK. From 2011 to 2014, she served as Vice President Global External Research and Development at Eli Lilly & Company, Inc., Indianapolis, IN, USA, where she led a global workforce delivering access to business critical external innovation. She was a member of the investment committees of Lilly Ventures and Lilly Asian Ventures and the steering committees of Lilly’s Capital Fund partners.

Prior to joining Eli Lilly, Dr Sullivan held various positions in the area of drug discovery and development at AstraZeneca from 1995 until 2010, including Vice President R&D, New Opportunities, from 2007 to 2010. In this role, she established and led AstraZeneca‘s virtual Therapy disease function which pinpointed new disease areas and created new therapeutic applications for multiple molecular entities and advanced them into the clinic. During her career, she gained extensive knowledge of various aspects of drug discovery and development having developed new molecules in virology, cancer, ophthalmology and respiratory and inflammation. Furthermore, she has particular expertise in origination, development and execution of innovative partnerships.

Since July 2015, Dr Elaine Sullivan has been serving as Non-executive Director of the IP Group plc. Dr Sullivan holds a doctorate in Molecular Biology and Virology from the University of Edinburgh, UK, and a bachelor’s degree in Molecular Biology from the University of Glasgow, UK.

Dr Elaine Sullivan (the former CEO of Carrick Therapeutics Ltd) is independent. Evotec SE holds approximately 4.5% of the shares in Carrick Therapeutics Ltd., and it is not a significant partner of Carrick Therapeutics Ltd. at present.

Therefore, for two reasons there is no conflict of interest that could hinder the position of independence:

  1. Evotec SE's participation rights in Carrick Therapeutics Ltd. are exercised by the Management Board of Evotec SE on its own responsibility pursuant to section 76 paragraph 1 of the German Stock Corporation Act (AktG). In particular, a member of the Supervisory Board has no influence on the voting on the resolutions of the shareholders of Carrick Therapeutics Ltd. (e.g. on any formal approval).
  2. There is also no intersecting executive body position, nor are there any other significant connections to members of the company's Management Board through their involvement in other companies or organisations.

 

Latest update: June 2021

Dr Constanze Ulmer-Eilfort Partner of the law firm Baker McKenzie, Member of the Global Executive Committee

Dr Ulmer-Eilfort has more than twenty years’ experience in advising high-tech, pharmaceutical and media companies on the protection and marketing of their intellectual property rights. She advises on a wide range of agreements, including cooperation and licensing agreements, R&D agreements and agreements with academic institutions. As a member of the Global Executive Committee of Baker McKenzie, Dr Ulmer-Eilfort chairs the Global Financial Committee and oversees the budgeting process and budget controls worldwide.

In addition, she is leading the reform of governance at Baker McKenzie, a multi-year project which includes the introduction of a new supervisory board that aims to support the engagement of partners, build trust and make management more accountable. Dr Ulmer-Eilfort’s leadership roles in both management and supervisory functions (e.g. as Chair of the Financial Committee) as well as her specialisation in the protection and marketing of intellectual property and corporate governance are an ideal qualification for her membership of the Supervisory Board of Evotec SE.

Dr Ulmer-Eilfort is to be considered as independent as she has no business relationship with Evotec SE and no other circumstances leading to dependency are apparent. She is chairwoman of the advisory committee of S4DX GmbH. Otherwise she is not a member of any statutory supervisory boards or similar domestic or foreign supervisory boards of commercial entities in accordance with Sec. 125 para. 1 sentence 5 AktG and recommendation C.14 of the German Corporate Governance Code as amended on 16 December 2019.

 

Latest update: June 2021

 

Supervisory Board   

As laid down in the current Articles of Association of Evote SE, the Supervisory Board consists of six members which are elected by the shareholders by simple majority vote at the Annual General Meeting. 

Please find more information about all current Supervisory Board members under this link.

The beginning and the end of the terms of office are shown in the table below:

Tenure and committee membership on the Supervisory Board 

Initial appointment to the Supervisory Board
 
End of tenure
 
Audit and Compliance Committee
Renumeration and Nomination Committee
Prof Dr Iris Löw-Friedrich (Chairwoman of the Supervisory Board)
2014
2024
X (Chair)
Roland Sackers (Vice Chairman of the Supervisory Board)
2019
2024
X (Chair)
X
Kasim Kutay
2020
2024
X
Dr Mario Polywka
2019
2024
X
Dr Elaine Sullivan
2015
2024
X
Dr Constanze Ulmer-Eilfort1)
2021
2024
X
Prof Dr Iris Löw-Friedrich (Chairwoman of the Supervisory Board)  
Initial appointment to the Supervisory Board
 
2014
End of tenure
 
2024
Audit and Compliance Committee
Renumeration and Nomination Committee X (Chair)
Roland Sackers (Vice Chairman of the Supervisory Board)  
Initial appointment to the Supervisory Board
 
2019
End of tenure
 
2024
Audit and Compliance Committee X (Chair)
Renumeration and Nomination Committee X
Kasim Kutay  
Initial appointment to the Supervisory Board
 
2020
End of tenure
 
2024
Audit and Compliance Committee
Renumeration and Nomination Committee X
Dr Mario Polywka  
Initial appointment to the Supervisory Board
 
2019
End of tenure
 
2024
Audit and Compliance Committee X
Renumeration and Nomination Committee
Dr Elaine Sullivan  
Initial appointment to the Supervisory Board
 
2015
End of tenure
 
2024
Audit and Compliance Committee
Renumeration and Nomination Committee X
Dr Constanze Ulmer-Eilfort1)  
Initial appointment to the Supervisory Board
 
2021
End of tenure
 
2024
Audit and Compliance Committee X
Renumeration and Nomination Committee

1) Member of the Supervisory Board since the AGM in June 2021

 

Composition of the Supervisory Board: Diversity and independency criteria fullfilled

In accordance with the Code’s recommendations, the members were appointed to the Supervisory Board regardless of gender, nationality or age based on the following criteria: qualification, work experience and competence, independence and diversity. However, the age limit set by the Supervisory Board determines that a candidate may not be older than 72 years at the time of the proposal. In addition, the Supervisory Board has agreed on two full terms as the regular limit of length of membership. Adequate female representation on the Supervisory Board is also intended with a gender quota requiring a minimum of 30% of men and women. 

Furthermore, the Supervisory Board has set specific targets for its composition and competencies and developed a Profile of Competencies and Expertise which reflects the company-specific situation. These targets and profiles provide that in consideration of the company-specific situation, the majority of the Supervisory Board members must have national and international experience in the following areas: (i) research and development, (ii) finance, capital markets, law, corporate governance, (iii) marketing, distribution and operations, and (iv) (public) health. In addition, thorough screening of candidates for the Supervisory Board early in the selection process is meant to avoid potential conflicts of interest. The Supervisory Board shall be composed in such a way that the majority of its members are independent and that its members as a group possess the knowledge, ability and expert experience required to properly complete its tasks.

Currently, the composition of Evotec’s Supervisory Board fulfils all those objectives: Five members are considered independent within the meaning of the German Corporate Governance Code. Three members are female, and two nationalities are represented on the Board. Only Dr Mario Polywka, who served as COO of Evotec until 31 December 2018 and who was elected to the Supervisory Board on the recommendations of a group of shareholders who together hold more than 25% of the total number of voting rights in the Company, is regarded as not independent. 

The current composition of the Supervisory Board fully represents the competence profile as set out above.

Research and Development
Finance, Capital Markets, Law, Corporate Governance
Marketing, Sale, Operating Business
(public) Health System
Nationality/ Age
Independence
Prof Dr Iris Löw-Friedrich (Chairwoman of the Supervisory Board)
X
X
1960
German
X
Roland Sackers (Vice Chairman of the Supervisory Board)
X
1968
German
X
Dr Mario Polywka
X
X
1963
British
Kasim Kutay
X
X
1965
British
X
Dr Elaine Sullivan
X
X
1961
British
X
Dr Constanze Ulmer-Eilfort
X
1962
German
X
Prof Dr Iris Löw-Friedrich (Chairwoman of the Supervisory Board)
Research and Development X
Finance, Capital Markets, Law, Corporate Governance
Marketing, Sale, Operating Business
(public) Health System X
Nationality/ Age 1960
German
Independence X
Roland Sackers (Vice Chairman of the Supervisory Board)
Research and Development
Finance, Capital Markets, Law, Corporate Governance X
Marketing, Sale, Operating Business
(public) Health System
Nationality/ Age 1968
German
Independence X
Dr Mario Polywka
Research and Development X
Finance, Capital Markets, Law, Corporate Governance
Marketing, Sale, Operating Business X
(public) Health System
Nationality/ Age 1963
British
Independence
Kasim Kutay
Research and Development
Finance, Capital Markets, Law, Corporate Governance X
Marketing, Sale, Operating Business X
(public) Health System
Nationality/ Age 1965
British
Independence X
Dr Elaine Sullivan
Research and Development X
Finance, Capital Markets, Law, Corporate Governance
Marketing, Sale, Operating Business X
(public) Health System
Nationality/ Age 1961
British
Independence X
Dr Constanze Ulmer-Eilfort
Research and Development
Finance, Capital Markets, Law, Corporate Governance
Marketing, Sale, Operating Business X
(public) Health System
Nationality/ Age 1962
German
Independence X

The members of the Supervisory Board assume full responsibility for any training and educational measures required for their duties.

 

Election of Supervisory Board Members

The Supervisory Board appoints a Chairman and a Vice Chairman from amongst its members. The Chairman of the Supervisory Board coordinates the work of the Supervisory Board and externally represents the concerns of the body. The Chairman is available to discuss issues pertaining to the Supervisory Board with investors upon request. 

The members of the Supervisory Board are elected for a period of five years and may be re-elected for a maximum of two full terms of office. 

The Supervisory Board appoints and dismisses the members of the Management Board and advises and oversees the Management Board in the management of the Company. The Management Board and the Supervisory Board maintain an open dialogue which is treated with confidentiality by both parties. The Supervisory Board, in particular the Chairman of the Supervisory Board, exchanges information with the Management Board on a regular basis. In numerous conference calls as needed, the Management Board continuously informed the Supervisory Board of the Company’s operational business and further current issues such as strategy, planning, risk management, and compliance management systems, providing in-depth analyses both orally and in writing.

Pursuant to Recommendation D.7 of the Code, the Supervisory Board held regular board meetings also without the attendance of the Management Board. 

More information about the Supervisory Board can be found in the Declaration of Corporate Management as well as in the Supervisory Board Report. Please find the respective documents for Download below.

 

Supervisory Board meetings

The articles of association provide that resolutions by the Supervisory Board shall typically be passed in meetings. However, in individual cases and upon the Chairman’s instruction, resolutions can be passed and meetings held by written notice, by telephone, by telex, by fax or by other means of telecommunication. The articles of association further provide that more than half of the members of the Supervisory Board must participate in voting on a resolution, either in person or in writing or in another permissible form, to constitute a quorum. If such a quorum is not met, a new meeting shall be called with a notice period of two weeks, in which case three present board members constitute a quorum. Absent members may participate in a resolution by delivering a written vote to the Supervisory Board. Resolutions of the Supervisory Board are passed by a simple majority of the votes cast.

The Supervisory Board has its own internal rules of procedure. Please find below the Rules of Procedure of the Supervisory Board for Download.

 

The activities of the Supervisory Board comply with the Corporate Governance Code

A significant proportion of the Supervisory Board’s work is conducted in committees. From among its members, Evotec’s Supervisory Board has established, pursuant to the German Stock Corporation Act and the recommendations of the Code, an Audit and Compliance Committee as well as a Remuneration and Nomination Committee. Members of both committees are appointed in accordance with the Code.

Evotec’s Audit and Compliance Committee, comprising three members, supports the Supervisory Board in independently overseeing the Company’s financial reporting activities and in auditing reports. In particular, the Audit and Compliance Committee scrutinises the Company’s accounting processes, the effectiveness of the internal control systems, and the audit. In this context, it discusses the quarterly and half-year reports as well as the risk management and compliance management systems with the Management Board. Within the scope of the audit of the financial statements commissioned by the Supervisory Board, the Audit and Compliance Committee also discusses certain steps and procedures of the audit with the appointed auditing firm, including the auditors’ independence, the additional services rendered by the auditor, the issuing of the audit mandate to the auditing firm, the determination of auditing focal points, the fee agreement and compliance issues. The members of the Audit Committee possess the required skills and experience. As Chief Financial Officer, Roland Sackers is not only independent but also has the required specialist knowledge and experience in the application of accounting principles and internal control processes. Neither the Chairman of the Supervisory Board nor a former member of the Management Board may become Chairman of the Audit Committee. The Audit and Compliance Committee meets at least four times per year.

Please find below the Audit Committee’s charter for Download.

The main duties and responsibilities of the Company’s Remuneration and Nomination Committee are to prepare the appointment of Management Board members and to prepare their remuneration system and Share Performance Plan. Decisions in this context are made by the full Supervisory Board. 

Members of committees are appointed in accordance with the Code. Detailed information on the composition of the Supervisory Board’s committees is shown in the table below.

Supervisory Board commitees

(as of June 2021)

Audit and Compliance CommitteeAudit and Compliance Committee
Remuneration and Nomination Committee
Prof. Dr Iris Löw-Friedrich (Chairperson)
X (Chair)
Roland Sackers (Vice Chairman)
X (Chair)
X
Kasim Kutay
X
Dr Mario Polywka
X
Dr Elaine Sullivan
X
Dr Constanze Ulmer-Eilfort1)
X
Prof. Dr Iris Löw-Friedrich (Chairperson)  
Audit and Compliance CommitteeAudit and Compliance Committee
Remuneration and Nomination Committee X (Chair)
Roland Sackers (Vice Chairman)  
Audit and Compliance CommitteeAudit and Compliance Committee X (Chair)
Remuneration and Nomination Committee X
Kasim Kutay  
Audit and Compliance CommitteeAudit and Compliance Committee
Remuneration and Nomination Committee X
Dr Mario Polywka  
Audit and Compliance CommitteeAudit and Compliance Committee X
Remuneration and Nomination Committee
Dr Elaine Sullivan  
Audit and Compliance CommitteeAudit and Compliance Committee
Remuneration and Nomination Committee X
Dr Constanze Ulmer-Eilfort1)  
Audit and Compliance CommitteeAudit and Compliance Committee X
Remuneration and Nomination Committee

1) In the Supervisory Board since AGM in June 2021

 

 Attendance at meetings of the Supervisory Board and its Comittees 2020

Supervisory Board member
Number of Supervisory Board and committee meetings
Participation
Presence*
Prof. Dr Wolfgang Plischke (Chairman)
4+4
4+4
100%
Prof. Dr Iris Löw-Friedrich (Vice Chairperson)
4+6
4+6
100%
Dr Mario Polywka
4+0
4+0
100%
Kasim Kutay1
2+2
2+2
100%
Roland Sackers
4+8
4+8
100%
Dr Michael Shalmi2
2+2
2+2
100%
Dr Elaine Sullivan
4+4
4+4
4+4
Supervisory Board member Prof. Dr Wolfgang Plischke (Chairman)
Number of Supervisory Board and committee meetings 4+4
Participation 4+4
Presence* 100%
Supervisory Board member Prof. Dr Iris Löw-Friedrich (Vice Chairperson)
Number of Supervisory Board and committee meetings 4+6
Participation 4+6
Presence* 100%
Supervisory Board member Dr Mario Polywka
Number of Supervisory Board and committee meetings 4+0
Participation 4+0
Presence* 100%
Supervisory Board member Kasim Kutay1
Number of Supervisory Board and committee meetings 2+2
Participation 2+2
Presence* 100%
Supervisory Board member Roland Sackers
Number of Supervisory Board and committee meetings 4+8
Participation 4+8
Presence* 100%
Supervisory Board member Dr Michael Shalmi2
Number of Supervisory Board and committee meetings 2+2
Participation 2+2
Presence* 100%
Supervisory Board member Dr Elaine Sullivan
Number of Supervisory Board and committee meetings 4+4
Participation 4+4
Presence* 4+4

* Commercially rounded
1 In the Supervisory Board since AGM in June 2020
2 In the Supervisory Board until AGM in June 2020

TOP